MTOR and non-small cell lung carcinoma: Here we assessed the combination of the mTOR inhibitor temsirolimus with the first-line chemotherapy for advanced NSCLC, cisplatin, and gemcitabine, to reduce cytotoxicity and enhance the therapeutic response.